World’s First COVID-19 Drug Based on Human Immunoglobulin Developed from Plasma of Recovered Patients
|
By HospiMedica International staff writers Posted on 14 Sep 2021 |

Illustration
The world’s first drug based on human immunoglobulin being developed from plasma of recovered patients could be effective on COVID-19 patients with mild conditions.
China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China) is developing two medicines for the treatment of COVID-19 based on human immunoglobulin and monoclonal antibody. Both the drugs could reduce the impact of the novel coronavirus in infected people and will be effective on patients with mild COVID-19, according to a report by the Global Times.
The first drug being developed from plasma of recovered COVID-19 patients or vaccinated uninfected people contains high-potency SARS-COV-2 neutralizing antibodies. The drug has demonstrated significant relief of symptoms and damage caused by SARS-COV-2 in pre-clinical studies and animal tests. The new drug containing a high level of neutralizing antibodies to the novel coronavirus is all set to soon enter Phase 3 clinical trials.
The second COVID-19 drug under development is based on a potent monoclonal antibody against the Delta variant discovered by researchers at Sinopharm. The monoclonal antibody is capable of effectively blocking the binding of the novel coronavirus to the Angiotensin-converting enzyme 2 which is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. According to Sinopharm, the antibody can prevent the SARS-COV-2 virus from infecting human cells.
Related Links:
China National Pharmaceutical Group Co., Ltd.
China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China) is developing two medicines for the treatment of COVID-19 based on human immunoglobulin and monoclonal antibody. Both the drugs could reduce the impact of the novel coronavirus in infected people and will be effective on patients with mild COVID-19, according to a report by the Global Times.
The first drug being developed from plasma of recovered COVID-19 patients or vaccinated uninfected people contains high-potency SARS-COV-2 neutralizing antibodies. The drug has demonstrated significant relief of symptoms and damage caused by SARS-COV-2 in pre-clinical studies and animal tests. The new drug containing a high level of neutralizing antibodies to the novel coronavirus is all set to soon enter Phase 3 clinical trials.
The second COVID-19 drug under development is based on a potent monoclonal antibody against the Delta variant discovered by researchers at Sinopharm. The monoclonal antibody is capable of effectively blocking the binding of the novel coronavirus to the Angiotensin-converting enzyme 2 which is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. According to Sinopharm, the antibody can prevent the SARS-COV-2 virus from infecting human cells.
Related Links:
China National Pharmaceutical Group Co., Ltd.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Optical Imaging System Helps Predict Chemotherapy Response in Cancer
Selecting chemotherapy can be difficult because tumors from different patients may respond differently to the same drug. Testing treatment effects directly on living tumor tissue could help clinicians... Read more
AI Tool Predicts Long-Term Cardiovascular Risk from Sleep Study ECG
Sleep disorders such as insomnia and obstructive sleep apnea are established cardiovascular risk factors and are commonly evaluated with overnight polysomnography. These studies routinely record electrocardiogram... Read more
Predictive Model Supports Growth Hormone Treatment Planning in Idiopathic Short Stature
Idiopathic short stature (ISS) describes children whose height is substantially below the expected range for age and sex without an identifiable medical cause. Recombinant growth hormone therapy can support... Read moreCritical Care
view channel
Proposed Risk Score Prioritizes Sickest Patients for Heart Transplant
Donor hearts remain extremely scarce in the U.S. transplant system, with one in five candidates dying or being removed from the waiting list before receiving an organ. Current allocation rules may also... Read more
Wearable Robotic Gait Training Linked to Improved Walking Distance in ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disease that damages nerve cells controlling voluntary muscles. As the disease advances, patients can lose the ability to walk, speak,... Read moreSurgical Techniques
view channel
New Surgical Technique Enlarges Aortic Root for Larger Valve Implantation
When replacing a diseased aortic valve, a small aortic root can prevent surgeons from implanting a prosthesis large enough for the patient’s body size. This can lead to patient-prosthesis mismatch, causing... Read moreFDA Approval Expands Bridging Stent Use in Complex Aortic Aneurysm Repair
Complex aortic aneurysms are increasingly treated with fenestrated and branched endovascular aortic repair, which rely on bridging stents to maintain blood flow to visceral arteries. These complex procedures... Read morePatient Care
view channel
AI Platform Personalizes Support Between Visits for Cancer Survivors
Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more
At-Home Neuromodulation Shows Promise in Selected Patients With Hypertension
High blood pressure is a major risk factor for cardiovascular disease, including heart attack and stroke. Many patients receiving treatment for hypertension still remain above recommended blood pressure... Read more
EHR Model Flags High-Risk Periods in Patients with Metastatic Breast Cancer
Determining when patients with metastatic breast cancer are nearing the end of life remains difficult, often leading to intensive interventions with limited benefit. Prognostic uncertainty can delay goals-of-care... Read moreMedical Imaging
view channel
MRI Tool Analysis Identifies Vascular Differences in Cerebral Small Vessel Disease
Cerebral small vessel disease (CSVD) involves changes or damage to the brain’s small blood vessels and is associated with stroke and cognitive impairment. Magnetic resonance imaging (MRI) can show cerebral... Read more
Privacy-Preserving Learning Model Adapts Adult Radiology AI for Neonatal Care
Artificial intelligence models may support radiology image interpretation, yet pediatric and neonatal care remain underserved. Privacy restrictions limit access to children’s medical records, and pediatric... Read more
Public Chest CT Dataset Supports Explainable AI in Diagnostic Radiology
Chest computed tomography scans generate complex three-dimensional images that can be difficult for artificial intelligence systems to explain clearly. Clinicians need to verify AI findings before using... Read more
PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI
Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read moreHealth IT
view channel
EHR Alerts Support Dosing, Sedation, and Shock Recognition in Cardiac Care
Electronic health record alerts can add to clinician workload when they are poorly targeted. In critical cardiac care, however, delayed decisions can affect treatment timing, sedation exposure, and escalation... Read more
Adaptive Radiation QA Software Gains Validation for NeoArc Treatments
Adaptive radiation therapy allows clinicians to adjust treatment plans to daily anatomical changes such as tumor shrinkage, weight loss, or organ movement, improving precision while limiting exposure to... Read morePoint of Care
view channel
Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes
Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
Microneedle Patch Enables At-Home Monitoring of Acute Kidney Injury
Kidney disease is often silent in its early stages, making timely detection difficult outside clinical settings. Early biomarkers such as neutrophil gelatinase–associated lipocalin can require blood draws... Read moreBusiness
view channel
Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma
Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read moreWorld Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition
World Health Expo (WHX) expands with the new Pharma, Biotech, Longevity and Wellness industry sectors More than 235,000 professional visits, over 4,200 exhibitors and representatives from over... Read more
Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery
As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more








